1289626-08-9

Upstream product

• 1289626-07-8 ethyl 4-(4-bromophenyl)-2-methyl-2-(methylsulfonyl)butanoate 
• 4654-39-1 4-bromophenethanol 
• 85356-68-9 1-bromo-4-(2-iodoethyl)benzene 

Downstream Products

• 1289626-34-1 (2R)-4-(4-bromophenyl)-2-methyl-2-(methylsulfonyl)butanoic acid (-)-ephedrine 
• 1289626-32-9 (2R)-4-(4-bromophenyl)-2-methyl-2-(methylsulfonyl)butanoic acid 
• 1289620-95-6 (+/-)-4-(4-bromophenyl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide 
• 1289626-83-0 (+/-)-2-methyl-2-(methylsulfonyl)-4-(4'-nitrobiphenyl-4-yl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide 
• 1289626-09-0 4-(4-bromophenyl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide 

Relevant academic research and scientific papers

Design, synthesis and structure-activity relationship evaluation of novel LpxC inhibitors as Gram-negative antibacterial agents

LpxC inhibitors are new-type antibacterial agents developed in the last twenty years, mainly against Gram-negative bacteria infections. To develop novel LpxC inhibitors with good antibacterial activities and biological metabolism, we summarized the basic skeleton of reported LpxC inhibitors, designed and synthesized several series of compounds and tested their antibacterial activities against Escherichial coli and Pseudomonas aeruginosa in vitro. Structure-activity relationships have been discussed in this article. The metabolism stability of YDL-2, YDL-5, YDL-8, YDL-14, YDL-20–YDL-23 have been evaluated in liver microsomes, which indicated that the 2-amino isopropyl group may be a preferred structure than the 2-hydroxy ethyl group in the design of LpxC inhibitors.

C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS

The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.